Join IAG’s Bio Partnering Team at Digital Sachs Spring Life Sciences Week
Our Bio-Partnering will attend Digital Sachs Spring Life Sciences Week, 28 February – 3 March 2022.
IAG’s partnering team are focused on building a diversified portfolio of innovative life science companies at various stages of clinical development.
IAG’s current portfolio consists of 10 biotech, pharma and digital health companies.
By bringing strategic collaborators and smart investments, we support novel drug or technology development efforts through conceptualisation, clinical trials to market entry.
Our portfolio companies take full advantage of a wide range of IAG’s innovative R&D solutions, operational breadth and expertise, risk-sharing financing and partnership models.
We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immune-oncology, oncology, inflammation, rheumatology, musculoskeletal, rare diseases, neuro-degenerative and immunology markets.
More on our recent partnerships can be found here: https://www.ia-grp.com/trial-solutions/bio-partnering/
About Digital Sachs Spring Life Sciences Week:
The 15th Annual ELSF is taking place on the 1st – 2nd of March and includes BioCapital & Investment Day and Bio-Pharma Partnering & Therapeutics Day. The two days features more than 12 hours of high-level speeches, panel discussions and spotlight showcases by leading industry corporates. In addition, there is a global company showcase combined of presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin
Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma.
The Invitation-only network for founders &CEOs of the most successful scaleups.
Dr Kubassova is a leading innovator and passionate investor in healthcare.
Presenting new data from Ulcerative Colitis trial at DDW 2023.